We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. uniQure N.V. is one of them. uniQure N.V. (NASDAQ:QURE) is a leading gene therapy company focused on developing transformative treatments for severe medical conditions. Its pipeline includes HEMGENIX for hemophilia B and AMT-130, a gene therapy candidate for Huntington’s disease, which has recently attracted significant attention. In late September 2025, uniQure N.V. (NASDAQ:QURE) announced positive topline results ...

LEXINGTON, Mass. and AMSTERDAM, Sept. 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 6,736,841 ordinary shares at a public offering price of $47.50 per share, which includes 947,368 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary s ...

智通财经APP获悉，高盛最新深度分析报告聚焦uniQure NV(QURE.US)基因疗法AMT-130在亨廷顿病治 疗中的突破性进展及商业前景。据披露，该疗法已在两项剂量组临床试验中展现显著疗效——高剂量组 17例患者完成36个月随访后，复合亨廷顿病评定量表显示疾病进展较自然病史减缓75%，总功能能力评 分变化减缓60%，脑脊液神经丝轻链蛋白水平平均下降8.2%;低剂量组12例患者虽未直接给出对比数 据，但整体趋势与高剂量组一致。生物标志物及多项次要终点指标均支持AMT-130的神经保护作用。近 日，该股已因为该疗法消息出现大涨。 在FDA加速批准路径下，uniQure计划于2026年第一季度提交生物制品许可申请，基于高剂量组三年期 的复合亨廷顿病评定量表(CUHDRS)变化数据，并采用ENROLL-HD自然病史数据集作为外部对照进行 倾向评分匹配分析。FDA已认可其制造工艺验证路径，要求补充全规模良好生产规范批次及单个工艺性 能确认批次以支持生物制品许可申请(BLA)提交。 安全性方面，自2022年12月起未新增严重不良事件，给药相关不良反应均已解决;第三队列联合免疫抑 制方案试验中，三例严重不良事件通过 ...

LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its previously announced underwritten public offering of 5,789,473 ordinary shares at a public offering price of $47.50 per share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase 526,316 of its ordinary shares at the public offering price pe ...

Cantor Fitzgerald upgraded UniQure NV (NASDAQ: QURE) to "Overweight" with a new price target of $80.UniQure's stock surged 248% after successful trial results for its Huntington's disease gene therapy.Analysts from Stifel, Leerink, and Mizuho have significantly raised their price targets for QURE, indicating strong confidence in its future performance.UniQure NV (NASDAQ: QURE) is a biotechnology company focused on developing gene therapies. It aims to provide innovative treatments for patients with severe g ...

Key Takeaways QURE stock soared 247.7% after AMT-130 met primary and secondary endpoints in Huntington's disease study.High-dose AMT-130 slowed disease progression by 75% on cUHDRS and 60% on TFC at 36 months.AMT-130 showed dose-dependent benefits on motor and cognitive function with a manageable safety profile.Shares of uniQure N.V. (QURE) skyrocketed 247.7% on Wednesday after the company reported meeting key goals in the pivotal early to mid-stage study of its investigational gene therapy, AMT-130, for th ...

We recently published 10 Stocks Crushing Wall Street, AI Stocks Dominate. Uniqure NV (NASDAQ:QURE) is one of the top performers on Tuesday. Shares of Uniqure NV soared by as much as 275 percent on Wednesday to hit a new all-time high as investors cheered stellar results from the clinical trial of its drug candidate for Huntington’s disease. During the session, shares of the company soared to its highest price of $51.21 before trimming gains to end the day just up by 247.73 percent at $47.50 apiece. Uniq ...

UniQure NV (NASDAQ: QURE) just staged one of biotech's wildest rides of the year, soaring 248% in a single session after unveiling successful trial results for its experimental Huntington's disease gene therapy. Indeed, the stock reached a 5-year high, marking its best session ever. But if you think the move was a one-off sugar high, Wall Street begs to differ.Track QURE stock here.Read Also: uniQure Stock Jumps On Positive News, But Risks RemainAnalysts Flip Bullish, Targets Race HigherThe clinical data di ...

盘前交易概况 - 美东时间周四上午7:35盘前交易出现显著活跃 多只股票呈现价格异动[1] - 盘前价格变动可能预示开盘后潜在交易机会 包括突破、反转或剧烈波动[1] - 早盘动量通常延续至常规交易时段 使盘前分析成为交易日关键组成部分[1] 涨幅显著股票 - PepGen Inc (PEPG) 股价上涨151%至6.68美元 位列涨幅榜首[3] - 22nd Century Group Inc (XXII) 上涨27%至1.93美元 涨幅排名第二[3] - Immuneering Corporation (IMRX) 上涨23%至11.36美元 位列涨幅第三[3] - uniQure N.V. (QURE) 上涨10%至52.58美元 锂业公司Lithium Americas Corp (LAC)同步上涨9%至6.60美元[3] - Jasper Therapeutics Inc (JSPR) 上涨9%至2.55美元 American Shared Hospital Services (AMS) 上涨8%至2.75美元[3] - PSQ Holdings Inc (PSQH) 上涨7%至3.06美元 K Wave Media Ltd (KWM) 同步上涨7%至2.48美元[3] - ClearPoint Neuro Inc (CLPT) 上涨5%至20.48美元 跻身涨幅前十[3] 跌幅显著股票 - Transocean Ltd (RIG) 下跌14%至3.11美元 领跌盘前交易[4] - Cyclerion Therapeutics Inc (CYCN) 下跌12%至2.83美元 跌幅排名第二[4] - CarMax Inc (KMX) 下跌11%至50.38美元 ARB IOT Group Limited (ARBB) 同步下跌11%至10.45美元[4] - SHF Holdings Inc (SHFS) 下跌10%至6.49美元 Digital Brands Group Inc (DBGI) 同步下跌10%至6.21美元[4] - Aqua Metals Inc (AQMS) 下跌9%至5.29美元 Akanda Corp (AKAN) 下跌8%至3.96美元[4] - Galecto Inc (GLTO) 下跌8%至3.88美元 Platinum Analytics Cayman Limited (PLTS) 下跌7%至11.12美元[4]

uniQure (QURE) shares rallied 247.7% in the last trading session to close at $47.5. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 13.5% loss over the past four weeks.The massive surge in the stock price was observed after QURE announced that its investigational gene therapy, AMT-130, achieved the primary and key secondary endpoints in a pivotal phase I/II study for Huntington’s disease. The high-dose treatm ...